Coronary microvasculature of ischemic myocardium

The **coronary microvasculature of ischemic myocardium** refers to the network of small blood vessels—including arterioles, capillaries, and venules—responsible for supplying oxygen and nutrients to the heart muscle, particularly under conditions of reduced blood flow (ischemia). This microvascular network is crucial for maintaining proper cardiac function, as it regulates perfusion based on oxygen demand through changes in vascular tone, and plays key roles in vascular resistance, barrier function, and tissue homeostasis[1][3][8]. During myocardial ischemia or ischemia-reperfusion injury, the microvasculature may suffer dysfunction, with mechanisms including endothelial cell swelling, impaired vasomotor regulation, inflammatory infiltration, microthrombosis, and microvascular obstruction ("no-reflow phenomenon")[1][3]. These structural and functional impairments directly contribute to the extent of myocardial injury, the response to treatments such as revascularization, and long-term morbidity and mortality in cardiovascular disease[1][3][8]. Damage or dysfunction of this microvascular bed is linked to several syndromes, including ischemia with no obstructive coronary artery disease (INOCA), microvascular angina, and microvascular obstruction after infarction[3][8]. The "ischemic myocardium microvasculature" is not a single molecule, enzyme, receptor, or classical therapeutic target. Rather, it is an anatomical and functional compartment comprising multiple cell types (endothelial cells, smooth muscle cells, pericytes) and signaling pathways. For this reason, "ischemic myocardium microvasculature" should not be listed as a canonical molecular target. Instead, the relevant molecular targets are the individual proteins and pathways expressed in these cells that mediate responses to ischemia, such as endothelial nitric oxide synthase (eNOS), ion channels, and receptors for vasoactive mediators[1][3]. Key points: - The term describes a tissue structure, not a discrete molecule or drug target. - Dysfunction of the microvasculature is a central mechanism in many cardiac diseases but is not itself a single therapeutic target; drugs address components or mechanisms within this system. - Interventions may target microvascular function broadly (e.g., vasodilators, anti-inflammatory agents), but not the "ischemic myocardium microvasculature" as a single target[1][3][8].

Other names

Coronary microvasculatureCardiac microvasculatureMicrovascular component of ischemic myocardiumMicrovascular coronary circulation